Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from CASI Pharmaceuticals ( (CASI) ).
On May 14, 2025, CASI Pharmaceuticals announced a management change with Mr. Daniel Lang stepping down as the Chief Financial Officer due to personal reasons. Deanna Qian will take over the role while continuing as the Global Controller, which may impact the company’s operational dynamics and strategic direction.
The most recent analyst rating on (CASI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals faces substantial financial difficulties, with declining revenues and increasing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score, highlighting the need for significant improvements in operational efficiency and revenue growth.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a Cayman incorporated biopharmaceutical company that focuses on developing and commercializing innovative therapeutics and pharmaceutical products.
Average Trading Volume: 9,400
Technical Sentiment Signal: Sell
Current Market Cap: $29.29M
For a thorough assessment of CASI stock, go to TipRanks’ Stock Analysis page.